Form 8-K

8-K — AdaptHealth Corp.

Accession: 0001628280-26-052149

Filed: 2026-08-04

Period: 2026-08-04

CIK: 0001725255

SIC: 8082 (SERVICES-HOME HEALTH CARE SERVICES)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — ahco-20260804.htm (Primary)

EX-99.1 (ahco-20260804x8k_ex991.htm)

GRAPHIC (adapthealthimg001a.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: ahco-20260804.htm · Sequence: 1

ahco-20260804

FALSE000172525500017252552026-08-042026-08-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________

FORM 8-K

___________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

August 4, 2026

Date of Report (date of earliest event reported)

AdaptHealth Corp.

(Exact name of registrant as specified in its charter)

Delaware

001-38399

82-3677704

(State or other jurisdiction of

incorporation or organization)

(Commission File Number)

(I.R.S. Employer Identification Number)

555 East North Lane, Suite 5075, Conshohocken, PA 19428

(Address of principal executive offices and zip code)

(610) 424-4515

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

AHCO

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 - Results of Operations and Financial Condition.

The following information is furnished pursuant to Regulation FD.

On August 4, 2026, AdaptHealth Corp. (the "Company") issued a press release (the “Press Release”) announcing financial results for the quarter ended June 30, 2026. A copy of the Press Release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by reference in such filing.

Item 9.01 - Financial Statements and Exhibits

(d) Exhibits

Exhibit No.

Description

99.1

Press Release dated August 4, 2026 announcing the earnings results for the quarter ended June 30, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Dated: August 4, 2026

AdaptHealth Corp.

By:

/s/ Jason Clemens

Name:

Jason Clemens

Title:

Chief Financial Officer

EX-99.1

Filename: ahco-20260804x8k_ex991.htm · Sequence: 2

Document

Exhibit 99.1

FOR IMMEDIATE RELEASE

ADAPTHEALTH CORP. ANNOUNCES SECOND QUARTER 2026 RESULTS

CONSHOHOCKEN, Pa. – August 4, 2026 - AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today financial results for the second quarter ended June 30, 2026.

Second Quarter Business Highlights

•Completed its first full quarter under the Company's exclusive capitated agreement with a large national integrated delivery network, with the contract now fully at run-rate.

•Signed a new capitated agreement with Humana OneHome in South Florida and Texas and successfully completed the transition of approximately 478,000 members.

•Subsequent to quarter-end, entered into a definitive agreement to sell the Company's Diabetes Health business for $235.0 million in cash, subject to customary purchase price adjustments, the most significant step yet in AdaptHealth's multi-year effort to concentrate its portfolio around its core Sleep Health, Respiratory Health, and supporting Wellness-at-Home businesses. The Diabetes Health business will now be presented as discontinued operations.

•Subsequent to quarter end, entered into a joint venture that combines the Company's eCommerce asset with a leading eCommerce sleep retailer and adds a home sleep test capability to help reach the vast undiagnosed OSA population.

•Grew registered myAPP users to more than 512,000, up 56% from year end 2025 and launched an AI-powered mask-fitting tool, advancing patient digital engagement and expanding self-service capabilities.

•Subsequent to quarter-end, redeemed the Company’s 6.125% Senior Notes due 2028 with the proceeds from the $325 million delayed draw term loan secured as part of the April 2026 refinancing.

•Completed a workforce restructuring, generating $19 million in annualized savings while maintaining full operational delivery across all functions.

Second Quarter Results

All comparisons are to the quarter ended June 30, 2025 unless otherwise stated. The amounts presented below reflect the Company’s continuing operations, except for cash flow from operations and free cash flow, which includes the cash flows from continuing operations and discontinued operations, see below for further discussion.

•Net revenue was $740.3 million compared to $657.1 million, an increase of 12.7%.

•Organic revenue growth of 15.9%, with growth across each of the Company’s reportable segments.

•Net loss attributable to AdaptHealth Corp. was $145.3 million compared to net income of $4.2 million, largely resulting from a $144.2 million pre-tax write down of goodwill.

•Adjusted EBITDA was $132.0 million compared to $136.4 million, a decrease of 3.2%.

•Cash flow from operations was $239.0 million year-to-date 2026, a decrease from $257.5 million during the comparable period in 2025, and free cash flow was negative $48.4 million year-to-date 2026, compared to $73.3 million during the comparable period in 2025.

-1 -

Management Commentary

“In the second quarter, we delivered 15.9% organic growth, with record volume gains across the business," said Suzanne Foster, Chief Executive Officer. "Also, in July we signed a definitive agreement to divest our Diabetes Health business, the most significant step yet in our multi-year effort to focus AdaptHealth on our core Sleep Health, Respiratory Health, and supporting Wellness-at-Home businesses. Our West Coast capitated partnership reached full scale in the quarter, and the complexity of that transition has impacted our margins. Together with an unexpected price increase from one of our manufacturers, this has led us to lower our full-year outlook. We are moving quickly to address the cost pressures introduced by our rapid growth, and we believe these actions will make us a stronger, more efficient company."

Financial Outlook

The Company is revising its financial guidance for fiscal year 2026 on a continuing operations basis, which excludes the Diabetes Health business, except for free cash flow, which includes the cash flows from continuing operations and discontinued operations, as follows:

•Net revenue of $2.85 billion to $2.89 billion

•Adjusted EBITDA of $490 million to $520 million

•Free cash flow of $80 million to $120 million

Relative to our prior fiscal year 2026 Adjusted EBITDA guidance of $680 million to $730 million, the revised guidance includes a $100 million impact from reporting the Diabetes Health business as discontinued operations, including $60 million of previously allocated corporate overhead that will remain in continuing operations, of which the Company expects roughly half to be eliminated within 12 months thereafter. The revised guidance also includes a $55 million impact related to our West Coast capitated contract; a $30 million impact from a manufacturer price increase; and a $15 million impact from other portfolio actions.

Conference Call

Management will host a teleconference today, Tuesday, August 4, 2026, at 8:30 am ET to discuss the results and business activities with analysts and investors.

Interested parties may participate in the call by dialing:

•800-274-8461 (Domestic) or

•203-518-9814 (International)

When prompted, reference Conference ID: AHCO2Q26

To access the Webcast, please go to the Company’s Investor Relations page at https://adapthealth.com/investorrelations/

Following the live call, a replay will be available for six months on the Company's website, www.adapthealth.com, under "Investor Relations."

About AdaptHealth Corp.

AdaptHealth is a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services. The Company operates under three reportable segments that align with its product categories: (i) Sleep Health, (ii) Respiratory Health, and (iii) Wellness at Home. The Sleep Health segment provides sleep therapy equipment, supplies and related services (including CPAP and BiLevel services) to individuals for the treatment of obstructive sleep apnea. The Respiratory Health segment provides oxygen and home mechanical ventilation equipment and supplies and related chronic therapy services to individuals for the treatment of respiratory diseases, such as chronic obstructive pulmonary disease and chronic respiratory failure. The Wellness at Home segment provides home medical equipment and services to patients in their homes including those who have been discharged from acute care and other facilities. The segment tailors a service model to patients who are adjusting to new lifestyles or navigating complex disease states by providing essential medical supplies and durable medical equipment.

-2 -

In July 2026, AdaptHealth entered into a definitive agreement to sell the Diabetes Health business for $235.0 million in cash, subject to customary purchase price adjustments. As a result of this transaction, the Diabetes Health business met the criteria to be reported as discontinued operations. Therefore, AdaptHealth has reported the results of the Diabetes Health business, including the results of operations, and related assets and liabilities, as discontinued operations for all periods presented herein.

The Company is proud to partner with an extensive and highly diversified network of referral sources, including acute care hospitals, sleep labs, pulmonologists, skilled nursing facilities, and clinics. AdaptHealth services beneficiaries of Medicare, Medicaid, and commercial insurance payors, reaching approximately 4.8 million patients annually in all 50 states through its network of approximately 670 locations in 48 states.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations and the Company’s acquisition pipeline. These statements are based on various assumptions and on the current expectations of AdaptHealth management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of the Company.

These forward-looking statements are subject to a number of risks and uncertainties, including the outcome of judicial and administrative proceedings to which the Company may become a party or governmental investigations to which the Company may become subject that could interrupt or limit the Company’s operations, result in adverse judgments, settlements or fines and create negative publicity; changes in the Company’s customers’ preferences, prospects and the competitive conditions prevailing in the healthcare sector. A further description of such risks and uncertainties can be found in the Company’s filings with the Securities and Exchange Commission. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that the Company presently knows or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect the Company’s expectations, plans or forecasts of future events and views as of the date of this press release. The Company anticipates that subsequent events and developments will cause the Company’s assessments to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Use of Non-GAAP Financial Information and Financial Guidance

The Company uses EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, free cash flow and organic revenue, which are financial measures that are not in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, to analyze its financial results and believes that they are useful to investors, as a supplement to U.S. GAAP measures. In addition, the Company’s ability to incur additional indebtedness and make investments under its existing credit agreement is governed, in part, by its ability to satisfy tests based on a variation of Adjusted EBITDA.

The Company believes Adjusted EBITDA and Adjusted EBITDA Margin are useful to investors in evaluating the Company’s financial performance. The Company uses Adjusted EBITDA as the profitability measure in its incentive compensation plans that have a profitability component and to evaluate acquisition opportunities, where it is most often used for purposes of contingent consideration arrangements.

-3 -

EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin should not be considered as measures of financial performance under U.S. GAAP, and the items excluded from EBITDA and Adjusted EBITDA are significant components in understanding and assessing financial performance. Accordingly, these key business metrics have limitations as an analytical tool. They should not be considered as an alternative to net income or any other performance measures derived in accordance with U.S. GAAP or as an alternative to cash flows from operating activities as a measure of the Company’s liquidity.

The Company uses free cash flow, which is a financial measure that is not in accordance with U.S. GAAP, in its operational and financial decision-making and believes free cash flow is useful to investors because similar measures are frequently used by securities analysts, investors, ratings agencies and other interested parties to evaluate the Company's competitors and to measure the ability of companies to service their debt. The Company's presentation of free cash flow should not be construed as a measure of liquidity or discretionary cash available to the Company to fund its cash needs, including investing in the growth of its business and meeting its obligations.

Free cash flow should not be considered as a measure of financial performance under U.S. GAAP. Accordingly, this key business metric has limitations as an analytical tool. It should not be considered as an alternative to any performance measures derived in accordance with U.S. GAAP or as an alternative to cash flows from operating activities as a measure of the Company’s liquidity.

The Company uses organic revenue, which is a financial measure that is not in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, to analyze its financial results and believes that it is useful to investors, as a supplement to U.S. GAAP measures. The change in net revenue from organic revenue is reported as organic revenue as a percentage of prior period total reported net revenue. Management believes organic revenue is meaningful to investors as it provides appropriate visibility into how the Company changes organically—that is, within its existing operations using its own resources.

Organic revenue is defined as all changes in reported net revenues from the comparable period presented, excluding: (1) increases in net revenue in the current period from acquisitions attributable to businesses and/or assets the Company has owned for less than one year based on the month of acquisition. This excludes the acquisition of assets from previous providers to facilitate the transition of patients related to newly awarded at-risk capitated contracts, since the revenue related to these agreements is earned organically; and (2) decreases in net revenue from dispositions existing in the prior period from divested product lines, services, and/or businesses for which there is no revenue recognized in the current period.

This release contains non-GAAP financial guidance. There is no reliable or reasonably estimable comparable GAAP measure for the Company’s non-GAAP financial guidance because the Company is not able to reliably predict the impact of certain items that typically have one or more of the following characteristics, such as being highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of future operating results. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods. As a result, reconciliation of the non-GAAP financial guidance to the most directly comparable GAAP measure is not available without unreasonable effort. In addition, the Company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. The variability of the specified items may have a significant and unpredictable impact on the Company’s future GAAP results.

In addition, the Company’s financial guidance in this release excludes the impact of any potential additional future strategic acquisitions and any items that have not yet been identified and quantified. The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this press release.

-4 -

ADAPTHEALTH CORP.

Condensed Consolidated Balance Sheets (Unaudited)

(in thousands) June 30, 2026 December 31, 2025

Assets

Current assets:

Cash $ 43,289 $ 106,136

Accounts receivable 390,389 370,897

Inventory 105,480 114,893

Prepaid and other current assets 90,219 100,619

Current assets held for sale - discontinued operations 168,098 36,354

Total current assets 797,475 728,899

Equipment and other fixed assets, net 656,368 503,193

Operating lease right-of-use assets 127,204 111,968

Finance lease right-of-use assets 44,801 52,300

Goodwill 2,370,431 2,457,627

Identifiable intangible assets, net 31,780 35,774

Deferred income taxes, net 290,720 267,786

Other assets 22,090 19,119

Noncurrent assets held for sale - discontinued operations — 139,911

Total Assets $ 4,340,869 $ 4,316,577

Liabilities and Stockholders' Equity

Current liabilities:

Accounts payable and accrued expenses $ 576,300 $ 553,700

Current portion of long-term debt 8,125 20,313

Current portion of operating lease obligations 36,030 30,728

Current portion of finance lease obligations 19,337 17,702

Contract liabilities 64,743 59,339

Other liabilities 4,117 30,106

Liabilities held for sale - discontinued operations 560 504

Total current liabilities 709,212 712,392

Long-term debt, less current portion 1,879,809 1,715,983

Operating lease obligations, less current portion 96,352 85,470

Finance lease obligations, less current portion 25,435 32,604

Other long-term liabilities 243,805 243,804

Total Liabilities 2,954,613 2,790,253

Total Stockholders' Equity 1,386,256 1,526,324

Total Liabilities and Stockholders' Equity $ 4,340,869 $ 4,316,577

-5 -

ADAPTHEALTH CORP.

Consolidated Statements of Operations (Unaudited)

Three Months Ended Six Months Ended

June 30, June 30,

(in thousands, except per share data) 2026 2025 2026 2025

Net revenue $ 740,307 $ 657,100 $ 1,420,180 $ 1,301,647

Costs and expenses:

Cost of net revenue 636,101 521,312 1,220,342 1,060,281

General and administrative expenses 96,093 95,263 189,977 180,158

Depreciation and amortization, excluding patient equipment depreciation 7,948 7,056 15,117 14,328

Goodwill impairment 144,236 — 144,236 —

Total costs and expenses 884,378 623,631 1,569,672 1,254,767

Gain on sale of businesses (6,269) (32,225) (6,269) (32,225)

Operating (loss) income (137,802) 65,694 (143,223) 79,105

Interest expense, net 26,209 27,533 51,803 55,932

Loss on extinguishment of debt 1,322 — 1,322 —

(Loss) income from continuing operations before income taxes (165,333) 38,161 (196,348) 23,173

Income tax (benefit) expense (21,227) 32,780 (28,392) 30,294

Net (loss) income from continuing operations (144,106) 5,381 (167,956) (7,121)

Net income from discontinued operations, net of tax 11,387 10,447 20,364 16,870

Net (loss) income (132,719) 15,828 (147,592) 9,749

Income attributable to noncontrolling interest 1,210 1,154 2,377 2,282

Net (loss) income attributable to AdaptHealth Corp. $ (133,929) $ 14,674 $ (149,969) $ 7,467

Weighted average common shares outstanding - basic 136,120 134,993 135,950 134,897

Weighted average common shares outstanding - diluted 136,120 137,071 135,950 134,897

Basic net (loss) income per share:

Continuing operations $ (1.07) $ 0.03 $ (1.25) $ (0.06)

Discontinued operations 0.08 0.07 0.15 0.11

Basic net (loss) income per share $ (0.99) $ 0.10 $ (1.10) $ 0.05

Diluted net (loss) income per share:

Continuing operations $ (1.07) $ 0.03 $ (1.25) $ (0.06)

Discontinued operations 0.08 0.07 0.15 0.11

Diluted net (loss) income per share $ (0.99) $ 0.10 $ (1.10) $ 0.05

-6 -

ADAPTHEALTH CORP.

Consolidated Statements of Cash Flows (Unaudited)

Six Months Ended

June 30,

(in thousands) 2026 2025

Cash flows from operating activities:

Net (loss) income $ (147,592) $ 9,749

Adjustments to reconcile net (loss) income to net cash provided by operating activities:

Depreciation and amortization, including patient equipment depreciation 226,766 186,705

Goodwill impairment 144,236 —

Equity-based compensation 12,089 11,427

Reduction in the carrying amount of operating lease right-of-use assets 21,299 15,300

Reduction in the carrying amount of finance lease right-of-use assets 10,081 7,096

Deferred income tax (benefit) expense (21,147) 12,643

Loss on extinguishment of debt 1,322 —

Amortization of deferred financing costs 2,326 3,105

Write-off of fixed assets 1,178 —

Gain on sale of businesses (6,269) (32,225)

Other (787) —

Changes in operating assets and liabilities, net of effects from acquisitions:

Accounts receivable (19,491) 8,868

Inventory 12,066 (9,713)

Prepaid and other assets 10,045 (4,578)

Operating lease obligations (20,351) (15,812)

Operating liabilities 13,253 64,956

Net cash provided by operating activities 239,024 257,521

Cash flows from investing activities:

Purchases of equipment and other fixed assets (287,456) (184,250)

Payments for business acquisitions, net of cash acquired (127,422) (18,561)

Proceeds from the sale of businesses, net of cash disposed 6,269 115,674

Proceeds from the sale of assets 1,439 —

Receipt of contingent consideration from the sale of assets — 1,156

Net cash used in investing activities (407,170) (85,981)

Cash flows from financing activities:

Proceeds from borrowings on long-term debt and lines of credit 575,000 —

Repayments on long-term debt and lines of credit (425,000) (175,000)

Repayments of finance lease obligations (8,118) (8,346)

Proceeds received in connection with employee stock purchase plan 951 564

Payments relating to the Tax Receivable Agreement (26,846) (25,012)

Payments of debt financing costs (5,038) —

Distributions to noncontrolling interests (2,349) (2,573)

Payments for tax withholdings from vesting of restricted stock units and stock option exercises (3,090) (2,079)

Payments of deferred purchase price from acquisitions (211) (211)

Net cash provided by (used in) financing activities 105,299 (212,657)

Net decrease in cash (62,847) (41,117)

Cash at beginning of period 106,136 109,747

Cash at end of period $ 43,289 $ 68,630

-7 -

ADAPTHEALTH CORP.

Non-GAAP Financial Measures

EBITDA and Adjusted EBITDA

This press release presents AdaptHealth’s EBITDA and Adjusted EBITDA for the three and six months ended June 30, 2026 and 2025.

AdaptHealth defines EBITDA as net income (loss) from continuing operations, plus interest expense, net, income tax expense (benefit), and depreciation and amortization, including patient depreciation.

AdaptHealth defines Adjusted EBITDA as EBITDA (as defined above), plus equity-based compensation expense, litigation settlement expense, gain on sale of businesses, restructuring expenses, loss on extinguishment of debt, goodwill impairment, and certain other non-recurring items of expense or income.

The following unaudited table presents the reconciliation of net income (loss) from continuing operations to EBITDA and Adjusted EBITDA, and the reconciliation of net income (loss) from continuing operations as a percentage of net revenue to Adjusted EBITDA Margin, for the three months ended June 30, 2026 and 2025:

Three Months Ended June 30,

2026 2025

(in thousands, except percentages) Dollars Revenue Percentage Dollars Revenue Percentage

(Unaudited)

Net (loss) income from continuing operations $ (144,106) (19.5)% $ 5,381 0.8%

Interest expense, net 26,209 3.5% 27,533 4.2%

Income tax (benefit) expense (21,227) (2.9)% 32,780 5.0%

Depreciation and amortization, including patient equipment depreciation 114,766 15.6% 86,925 13.2%

EBITDA (24,358) (3.3)% 152,619 23.2%

Equity-based compensation expense (a) 5,398 0.7% 6,010 0.9%

Gain on sale of businesses (b) (6,269) (0.8)% (32,225) (4.9)%

Restructuring expenses (c) 6,070 0.7% — —%

Loss on extinguishment of debt (d) 1,322 0.2% — —%

Goodwill impairment (e) 144,236 19.5% — —%

Other non-recurring expenses, net (f) 5,594 0.8% 10,015 1.6%

Adjusted EBITDA $ 131,993 17.8% $ 136,419 20.8%

Adjusted EBITDA Margin 17.8% 20.8%

-8 -

ADAPTHEALTH CORP.

(a) Represents equity-based compensation expense for awards granted to employees and non-employee directors.

(b) Represents pre-tax gains associated with the dispositions of two businesses within the Company's Wellness at Home segment.

(d) Represents third-party fees and the write-off of unamortized deferred financing costs in connection with the refinancing of the Company's credit agreement.

(e)

Represents non-cash goodwill impairment charges as a result of the fair values of the Company's Respiratory Health and Wellness at Home reporting units being less than their respective carrying values.

(f)

The 2026 period consists of $2.7 million of consulting expenses associated with asset dispositions, $1.4 million of transaction costs associated with acquisitions, and $1.5 million of other non-recurring expenses. The 2025 period consists of $6.9 million of consulting expenses associated with asset dispositions (of which $5.1 million relates to contingent success fees from the sales of businesses), $1.0 million of transaction costs associated with acquisitions, and $2.1 million of other non-recurring expenses.

Six Months Ended June 30,

2026 2025

(in thousands, except percentages) Dollars Revenue Percentage Dollars Revenue Percentage

(Unaudited)

Net loss from continuing operations $ (167,956) (11.8)% $ (7,121) (0.5)%

Interest expense, net 51,803 3.6% 55,932 4.3%

Income tax (benefit) expense (28,392) (2.0)% 30,294 2.3%

Depreciation and amortization, including patient equipment depreciation 215,683 15.2% 175,866 13.5%

EBITDA 71,138 5.0% 254,971 19.6%

Equity-based compensation expense (a) 11,764 0.8% 11,202 0.9%

Litigation settlement expense (b) 500 —% — —%

Gain on sale of businesses (c) (6,269) (0.4)% (32,225) (2.5)%

Restructuring expenses (d) 6,070 0.4% — —%

Loss on extinguishment of debt (e) 1,322 0.1% — —%

Goodwill impairment (f) 144,236 10.2% — —%

Other non-recurring expenses, net (g) 7,797 0.6% 15,141 1.1%

Adjusted EBITDA $ 236,558 16.7% $ 249,089 19.1%

Adjusted EBITDA Margin 16.7% 19.1%

-9 -

ADAPTHEALTH CORP.

(a) Represents equity-based compensation expense for awards granted to employees and non-employee directors.

(b) Represents an estimated expense to settle a shareholder derivative complaint.

(c) Represents pre-tax gains associated with the dispositions of two businesses within the Company's Wellness at Home segment.

(d) Represents expenses related to a cost savings plan that was implemented in June 2026.

(e) Represents third-party fees and the write-off of unamortized deferred financing costs in connection with the refinancing of the Company's credit agreement.

(f) Represents non-cash goodwill impairment charges as a result of the fair values of the Company's Respiratory Health and Wellness at Home reporting units being less than their respective carrying values.

(g)

The 2026 period consists of $4.3 million of consulting expenses associated with asset dispositions, $2.2 million of transaction costs associated with acquisitions, and $1.3 million of other non-recurring expenses. The 2025 period consists of $9.2 million of consulting expenses associated with asset dispositions (of which $5.1 million relates to contingent success fees from the sales of businesses), $2.0 million of consulting expenses associated with systems implementation activities, $1.1 million of transaction costs associated with acquisitions, and $2.8 million of other non-recurring expenses.

-10 -

ADAPTHEALTH CORP.

Free Cash Flow

This press release presents AdaptHealth’s free cash flow for the three and six months ended June 30, 2026 and 2025.

AdaptHealth defines free cash flow as net cash provided by operating activities less cash paid for purchases of equipment and other fixed assets.

The following unaudited table reconciles net cash provided by operating activities to free cash flow for the three and six months ended June 30, 2026 and 2025:

Three Months Ended Six Months Ended

(in thousands) June 30, June 30,

2026 2025 2026 2025

Net cash provided by operating activities $ 145,302 $ 161,994 $ 239,024 $ 257,521

Purchases of equipment and other fixed assets (166,244) (88,665) (287,456) (184,250)

Free cash flow $ (20,942) $ 73,329 $ (48,432) $ 73,271

Contacts

AdaptHealth Corp.

Jason Clemens, CFA

Chief Financial Officer

Luke Montgomery, CFA

Senior Vice President, Investor Relations

IR@adapthealth.com

-11 -

GRAPHIC

Filename: adapthealthimg001a.jpg · Sequence: 6

Binary file (5327 bytes)

Download adapthealthimg001a.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Aug. 04, 2026

Cover [Abstract]

Document Type

8-K

Document Period End Date

Aug. 04, 2026

Entity Registrant Name

AdaptHealth Corp.

Entity Incorporation, State or Country Code

Entity File Number

001-38399

Entity Tax Identification Number

82-3677704

Entity Address, State or Province

Entity Address, Postal Zip Code

19428

Entity Address, Address Line Two

Suite 5075

Entity Address, Address Line One

555 East North Lane

Entity Address, City or Town

Conshohocken

City Area Code

610

Local Phone Number

424-4515

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.0001 per share

Trading Symbol

AHCO

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

Amendment Flag

false

Entity Central Index Key

0001725255

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration